Quantum-Si shares surged 24.39% to $0.98 after the company presented interim Proteus data at HUPO 2026, describing stronger performance than its Platinum Pro platform. In a control peptide study, Proteus generated a median 30 times more alignments from a single chamber, identified all six peptides in every run and recorded a median false discovery rate of 1.36%, versus 6.58% for Platinum Pro. Quantum-Si projected that a four-chamber Proteus run could produce about 60 times more alignments than a two-chamber Platinum Pro run. Proteus also identified 1.6 to 2.0 times more peptides in protein mixtures, detected all 24 proteins in a separate panel and measured 4.3 times more amino acids per run. Trading volume reached 20.54 million shares, roughly seven times the 100-day average of 2.85 million shares.